sorafenib has been researched along with gsk 1363089 in 9 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (gsk 1363089) | Trials (gsk 1363089) | Recent Studies (post-2010) (gsk 1363089) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 131 | 9 | 124 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Gong, P; Gu, Y; Lu, K; Ma, J; Qin, M; Wang, L; Wang, Y; Xie, H; Zhai, X | 1 |
| Ding, K; Li, Y; Lu, X; Ren, X | 1 |
| Guo, M; He, J; Jiang, X; Jiang, Y; Li, J; Liu, J; Ouyang, L; Wang, J; Zhang, J; Zhang, S | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Liu, Y; Xu, Z; Zhao, SJ | 1 |
| Berger, BT; Chaikuad, A; Drápela, S; Knapp, S; Maier, L; Němec, V; Paruch, K; Souček, K | 1 |
| Shi, K; Wang, J; Wang, Y; Zhang, J; Zhou, E | 1 |
4 review(s) available for sorafenib and gsk 1363089
| Article | Year |
|---|---|
Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.
Topics: Amino Acid Sequence; Animals; Discoidin Domain Receptors; Drug Discovery; Humans; Inflammation; Ligands; Models, Molecular; Molecular Sequence Data; Neoplasms; Protein Conformation; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; Small Molecule Libraries | 2015 |
Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.
Topics: Antineoplastic Agents; Drug Discovery; Humans; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridines; Quinazolines; Quinolones; Receptors, Vascular Endothelial Growth Factor; Small Molecule Libraries | 2016 |
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles | 2019 |
Small-Molecule Receptor-Interacting Protein 1 (RIP1) Inhibitors as Therapeutic Agents for Multifaceted Diseases: Current Medicinal Chemistry Insights and Emerging Opportunities.
Topics: Apoptosis; Chemistry, Pharmaceutical; Drug Discovery; Humans; Receptor-Interacting Protein Serine-Threonine Kinases | 2022 |
5 other study(ies) available for sorafenib and gsk 1363089
| Article | Year |
|---|---|
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Design and synthesis of novel 2-(4-(2-(dimethylamino)ethyl)-4H-1,2,4-triazol-3-yl)pyridines as potential antitumor agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; HT29 Cells; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrimidines; Structure-Activity Relationship; Triazoles | 2014 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Highly selective inhibitors of protein kinases CLK and HIPK with the furo[3,2-b]pyridine core.
Topics: Animals; Carrier Proteins; Crystallography, X-Ray; Furans; Humans; MCF-7 Cells; Mice; Molecular Structure; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Structure-Activity Relationship | 2021 |